Randomized double-blind placebo controlled crossover trial documenting oral lorcainide efficacy in suppression of symptomatic ventricular tachyarrhythmias.

@article{Keefe1982RandomizedDP,
  title={Randomized double-blind placebo controlled crossover trial documenting oral lorcainide efficacy in suppression of symptomatic ventricular tachyarrhythmias.},
  author={D. Keefe and F. Peters and R. Winkle},
  journal={American heart journal},
  year={1982},
  volume={103 4 Pt 1},
  pages={
          511-8
        }
}
  • D. Keefe, F. Peters, R. Winkle
  • Published 1982
  • Medicine
  • American heart journal
  • Lorcainide, a new antiarrhythmic drug, was given to 10 patients with frequent (greater than 1/min) premature ventricular contractions (PVCs) on a baseline 24-hour Holter monitor. Each patient received lorcainide, 100 mg twice daily, and an identical placebo, in a randomized double-blind crossover trial, with 1 week in each treatment period. Before the trial and at the end of each period, routine laboratory, clinical evaluation, 12-lead ECG's, and 24-hour ambulatory ECG recordings were performed… CONTINUE READING
    36 Citations
    Antiarrhythmic Effect of Lorcainide in Patients Taking Digoxin
    Lorcainide in patients with refractory ventricular tachyarrhythmia.
    • 23

    References

    SHOWING 1-9 OF 9 REFERENCES
    Lorcainide; II. Plasma concentration‐effect relationship
    • 60
    Antiarrhythmic, electrophysiologic and hemodynamic effects of lorcainide.
    • 47
    Clinical experience with lorcainide (R 15 889), a new anti-arrhythmic drug.
    • 28
    Lorcainide; I. Saturable presystemic elimination
    • 57